via IBM Research
Antibiotic resistance is no joke. It’s a huge threat to human health — even more so during the raging pandemic. We need new antibiotics, and we need them fast.
In the US alone, nearly three million people¹ get infected with antibiotic-resistant bacteria or fungi every year¹. But very few new antibiotics are being developed to replace those that no longer work. That’s because drug design is an extremely difficult and lengthy process — there are more possible chemical combinations of a new molecule than there are atoms in the Universe.
We want to help.
Paving the way to the era of Accelerated Discovery, our IBM Research team has developed an AI system that can help speed up the design of molecules for novel antibiotics. And it works — in “Accelerating Antimicrobial Discovery with Controllable Deep Generative Models and Molecular Dynamics,” published in Nature Biomedical Engineering, we outline how we used it to create two new non-toxic antimicrobial peptides (AMPs) with strong broad-spectrum potency. Peptides are small molecules — they are short strings of amino acids, the building blocks of proteins. Our approach outperforms other leading de novo AMP design methods by nearly 10 percent.
Beyond antibiotics, this generative AI system could potentially accelerate the design process of the best possible molecules for new drugs and materials — helping scientists to use AI to discover and design better candidates for more effective drugs and therapies for diseases, materials to absorb and capture carbon to help fight climate change, materials for more intelligent energy production and storage, and much more. To fight these challenges, we need to accelerate the rate of discovery of new and functional molecules — at scale.
Where is that molecule?
That’s far from easy. Zeroing in on the correct molecular configuration that would lead to a new material with desired properties among the astronomical number of possible molecules is like looking for a needle in a haystack. For peptides, one would typically have to experimentally screen more than a hundred molecules to find one with the right properties.
So we’ve turned to AI for help.
First, we used an AI generative model dubbed a deep generative autoencoder to learn about the vast space of known peptide molecules. The model captured meaningful information such as molecular similarity and function about diverse peptide sequences, enabling us to explore beyond known antimicrobial templates.
We then applied Controlled Latent attribute Space Sampling (CLaSS) — a recently developed computational method for generating novel peptide molecules with custom properties. It works by sampling from the informative latent space of peptides and relies on a rejection sampling scheme guided by the molecular property the classifier trained on during the latent representation. Since CLaSS performs attribute-conditioned sampling in the compressed latent space, it is a computationally efficient and scalable approach that can be easily repurposed.
We then used deep learning classifiers to screen the AI-generated candidate antimicrobial molecules for additional key attributes, such as toxicity and broad-spectrum activity. We performed additional screening with the help of high-throughput, coarse-grained molecular dynamics simulations. These simulations look for presence of novel physicochemical features indicative of stable and peptide-membrane binding, such as low-contact variance between peptide and membrane.
Within 48 days, our AI-boosted molecular design approach to Accelerated Discovery enabled us to identify, synthesize, and experimentally test 20 AI-generated novel candidate antimicrobial peptides. Two of them turned out to be highly potent against diverse Gram-positive and Gram-negative pathogens (including multidrug-resistant K. pneumoniae) and very unlikely to trigger drug resistance in E. coli.
We also didn’t find any cross-resistance for either of the AMPs when tested using a polymyxin-resistant strain. Live-cell confocal imaging showed the formation of membrane pores as the underlying mechanism of bactericidal mode of action of these peptides. Both antimicrobials have low toxicity — we tested them in vitro and also in mice, providing important information about the safety, toxicity and efficacy of these antimicrobial candidates in a complex animal model.
Our proposed approach could potentially lead to faster and more efficient discovery of potent and selective broad-spectrum antimicrobials to keep antibiotic-resistant bacteria at bay — for good. And we hope that our AI could also be used to help address the world’s other most difficult discovery challenges, such as designing new therapeutics, environmentally friendly and sustainable photoresists, new catalysts for more efficient carbon capture, and so much more.
Original Article: IBM AI finds new peptides – paving the way to better drug design
More from: IBM Research
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
New antibiotics
- Changes in pig farming in the 20th century spread antibiotic-resistant Salmonella around the world, finds study
Historical changes in pig farming led to the global spread of Salmonella, resistant to antibiotics—a new international study led by researchers at the University of Warwick suggests. ...
- A mother's loss launches a global effort to fight antibiotic resistance
In November 2017, days after her daughter Mallory Smith died from a drug-resistant infection at the age of 25, Diane Shader Smith typed a password into Mallory's laptop.
- A New Oral Antibiotic Is Available to Treat UTIs
The FDA recently approved Pivya for uncomplicated UTIs. Pivya is an oral tablet that clears bacterial infections in the female bladder.
- DeepMind’s new AlphaFold 3 expands to DNA, RNA modeling
Google DeepMind expands its AlphaFold AI system to model how proteins interact with other cell structures including DNA and RNA.
- Recce Pharmaceuticals Granted New Patent in China for RECCE® Anti-Infectives
2 About Recce Pharmaceuticals Ltd Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is developing a New Class of Synthetic Anti-Infectives designed to address the urgent global health problems of ...
Go deeper with Google Headlines on:
New antibiotics
[google_news title=”” keyword=”new antibiotics” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Antibiotic development
- DA: 10 arrested on drug charges, creating ‘problem property’ in East Boston housing development
The building was allegedly responsible for 52 drug-related police interactions between January 2023 and April 2024.
- Google DeepMind Unveils Next-Gen AI Drug Discovery Model
The third version of the "AlphaFold" AI model will help scientists target diseases and design new medications.
- A mother's loss launches a global effort to fight antibiotic resistance
In November 2017, days after her daughter Mallory Smith died from a drug-resistant infection at the age of 25, Diane Shader Smith typed a password into Mallory's laptop.
- Global Companion Diagnostics Research Report 2024-2029: Innovations in Companion Diagnostics Boost Drug Development and Personalized Medicine
Factors such as the increasing importance of companion diagnostics in drug development, rising cancer incidence, and the growing adoption of targeted therapies are driving market growth.
- Systemic Antibiotics in First Year of Life Tied to Higher Atopic Dermatitis Risk
Systemic antibiotic exposure in the first year of life is associated with higher atopic dermatitis (AD) risk in a dose-response fashion, according to a study published online April 24 in the Journal ...
Go deeper with Google Headlines on:
Antibiotic development
[google_news title=”” keyword=”antibiotic development” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
[embedyt] https://www.youtube.com/embed?listType=playlist&list=PL0UjJ07OSXC83oV409r1yRju8-ihA1InJ&layout=gallery[/embedyt]